CLINICAL TRIAL OF IOHEXOL IN 60 CASES UNDERGOINGMYELOGRAPHY

Iohexol (omnipaque) has been used in clinicaltrials in 60 myelographs. The image quality wasgood to excellent. Manifestations of neurologicsigns and psychic symptoms were noted, but therewere no severe adverse effects. More common reac-tive symptoms in the series were mild headache(18%) and dizziness (15'/o). EEGs were taken iii20 cases before and after myelography. There wereno significant changes. The conclusions were:Iohexol is a new nonionic contrast medium in theaqueous state with low neurotoxicity and high pa-tient tolerance appropriate for intrathecal use.